AARD
Aardvark Therapeutics, Inc.
Price Chart
Latest Quote
$13.30
Current Price| Previous Close | $12.99 |
| Open | $12.84 |
| Day High | $13.52 |
| Day Low | $12.80 |
| Volume | 147,832 |
Stock Information
| Shares Outstanding | 21.77M |
| Total Debt | $545K |
| Cash Equivalents | $126.35M |
| Net Income | $-48.77M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $289.58M |
| EPS (TTM) | $-2.53 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 22/42| Debt to Equity | -0.01 |
| Debt to Earnings | -0.04 |
| Current Ratio | 15.05 |
| Quick Ratio | 14.95 |
| Return on Equity | 37.68% |
| Avg FCF Growth | 24.20% |
| FCF Yield | -6.28% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $13.30 | 149,419 |
| 2026-01-30 | $12.99 | 168,400 |
| 2026-01-29 | $13.35 | 126,400 |
| 2026-01-28 | $13.25 | 208,700 |
| 2026-01-27 | $14.70 | 132,000 |
| 2026-01-26 | $14.76 | 118,700 |
| 2026-01-23 | $15.01 | 118,000 |
| 2026-01-22 | $15.08 | 266,100 |
| 2026-01-21 | $15.82 | 253,700 |
| 2026-01-20 | $15.52 | 290,600 |
| 2026-01-16 | $15.37 | 137,600 |
| 2026-01-15 | $15.35 | 158,000 |
| 2026-01-14 | $14.98 | 254,700 |
| 2026-01-13 | $15.39 | 324,300 |
| 2026-01-12 | $14.84 | 399,700 |
| 2026-01-09 | $14.27 | 106,000 |
| 2026-01-08 | $14.51 | 143,700 |
| 2026-01-07 | $13.70 | 129,100 |
| 2026-01-06 | $13.31 | 124,400 |
| 2026-01-05 | $13.28 | 136,300 |
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
📰 Latest News
Aardvark Therapeutics, Inc. (NASDAQ:AARD) stock most popular amongst retail investors who own 32%, while private equity firms hold 28%
Simply Wall St. • 2026-01-19T19:08:59Z
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls
The Fly • 2025-12-23T14:33:17Z
Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win
Investor's Business Daily • 2025-12-11T21:27:17Z
Datadog, Trade Desk upgraded: Wall Street's top analyst calls
The Fly • 2025-11-07T14:33:08Z
Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment
Insider Monkey • 2025-10-17T13:27:16Z
MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug
BioPharma Dive • 2025-09-22T12:01:00Z
Insider Stock Buying Reaches US$730.4k On Aardvark Therapeutics
Simply Wall St. • 2025-09-22T10:43:33Z
LB Pharmaceuticals raises $285 million in US IPO
Reuters • 2025-09-11T01:23:49ZLB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought
Reuters • 2025-09-08T14:41:23Z2 ‘Strong Buy’ Growth Stocks Offering 300% or Higher Upside
Barchart • 2025-09-02T11:30:02Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Expenses | $22,668,000 | $6,653,000 | $10,874,000 |
| Other Income Expense | $-334,000 | $-1,978,000 | $-2,810,000 |
| Net Non Operating Interest Income Expense | $2,414,000 | $1,423,000 | $120,000 |
| Operating Expense | $22,668,000 | $6,653,000 | $10,874,000 |
| General And Administrative Expense | $5,305,000 | $2,173,000 | $2,702,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Interest Income | $2,414,000 | $1,423,000 | $120,000 |
| Interest Income | $2,414,000 | $1,423,000 | $120,000 |
| Normalized Income | $-20,254,000 | $-5,230,000 | $-10,754,000 |
| Net Income From Continuing And Discontinued Operation | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Total Operating Income As Reported | $-22,785,000 | $-7,415,000 | $-11,363,000 |
| Net Income Common Stockholders | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Income | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Income Including Noncontrolling Interests | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Income Continuous Operations | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Pretax Income | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Special Income Charges | $-117,000 | $-762,000 | $-489,000 |
| Interest Income Non Operating | $2,414,000 | $1,423,000 | $120,000 |
| Operating Income | $-22,668,000 | $-6,653,000 | $-10,874,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Diluted EPS | $-0.96 | $-0.56 | $-1.39 |
| Basic EPS | $-0.96 | $-0.56 | $-1.39 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-22,318,000 | $-4,675,000 | $-7,954,000 |
| Total Unusual Items | $-334,000 | $-1,978,000 | $-2,810,000 |
| Total Unusual Items Excluding Goodwill | $-334,000 | $-1,978,000 | $-2,810,000 |
| Reconciled Depreciation | $16,000 | $0 | $110,000 |
| EBITDA (Bullshit earnings) | $-22,652,000 | $-6,653,000 | $-10,764,000 |
| EBIT | $-22,668,000 | $-6,653,000 | $-10,874,000 |
| Diluted Average Shares | $21,384,377 | $12,909,267 | $9,732,784 |
| Basic Average Shares | $21,384,377 | $12,909,267 | $9,732,784 |
| Diluted NI Availto Com Stockholders | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Write Off | $117,000 | $762,000 | $489,000 |
| Gain On Sale Of Security | $-217,000 | $-1,216,000 | $-2,321,000 |
| Provision For Doubtful Accounts | $117,000 | $0 | $1,000,000 |
| Research And Development | $17,363,000 | $4,480,000 | $7,172,000 |
| Selling General And Administration | $5,305,000 | $2,173,000 | $2,702,000 |
| Other Gand A | $5,305,000 | $2,173,000 | $2,702,000 |
| Other Special Charges | - | - | $1,000,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Tangible Assets | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Total Assets | $77,507,000 | $10,536,000 | $16,757,000 |
| Total Non Current Assets | $3,370,000 | $168,000 | $266,000 |
| Other Non Current Assets | $2,635,000 | $13,000 | $14,000 |
| Current Assets | $74,137,000 | $10,368,000 | $16,491,000 |
| Other Current Assets | $160,000 | $127,000 | $70,000 |
| Prepaid Assets | $314,000 | $252,000 | $316,000 |
| Cash Cash Equivalents And Short Term Investments | $73,663,000 | $9,989,000 | $16,105,000 |
| Cash And Cash Equivalents | $61,641,000 | $9,735,000 | $15,559,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Debt | $779,000 | $162,000 | $262,000 |
| Long Term Debt And Capital Lease Obligation | $441,000 | $50,000 | $162,000 |
| Current Debt And Capital Lease Obligation | $338,000 | $112,000 | $100,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Liabilities Net Minority Interest | $132,150,000 | $45,338,000 | $44,680,000 |
| Total Non Current Liabilities Net Minority Interest | $127,223,000 | $43,956,000 | $44,085,000 |
| Other Non Current Liabilities | $26,000 | $2,000 | $19,000 |
| Current Liabilities | $4,927,000 | $1,382,000 | $595,000 |
| Current Deferred Liabilities | $671,000 | $0 | - |
| Payables And Accrued Expenses | $3,693,000 | $1,225,000 | $442,000 |
| Payables | $2,298,000 | $1,035,000 | $259,000 |
| Accounts Payable | $2,298,000 | $1,035,000 | $259,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Common Stock Equity | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Total Equity Gross Minority Interest | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Stockholders Equity | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Retained Earnings | $-58,327,000 | $-37,739,000 | $-30,531,000 |
| Preferred Securities Outside Stock Equity | $126,756,000 | $43,904,000 | $43,904,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Ordinary Shares Number | $21,688,172 | $21,384,377 | $21,384,377 |
| Share Issued | $21,688,172 | $21,384,377 | $21,384,377 |
| Tangible Book Value | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Invested Capital | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Working Capital | $69,210,000 | $8,986,000 | $15,896,000 |
| Capital Lease Obligations | $779,000 | $162,000 | $262,000 |
| Total Capitalization | $-54,643,000 | $-34,802,000 | $-27,923,000 |
| Additional Paid In Capital | $3,684,000 | $2,937,000 | $2,608,000 |
| Capital Stock | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $441,000 | $50,000 | $162,000 |
| Current Capital Lease Obligation | $338,000 | $112,000 | $100,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $225,000 | $45,000 | $53,000 |
| Current Accrued Expenses | $1,395,000 | $190,000 | $183,000 |
| Net PPE | $735,000 | $155,000 | $252,000 |
| Gross PPE | $735,000 | $155,000 | $252,000 |
| Other Properties | $735,000 | $155,000 | $252,000 |
| Other Short Term Investments | $12,022,000 | $254,000 | $546,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | $-18,196,000 | $-5,824,000 | $-10,543,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Cash Flow | $-18,087,000 | $-5,824,000 | $-10,543,000 |
| Cash Flow From Continuing Operating Activities | $-18,087,000 | $-5,824,000 | $-10,543,000 |
| Operating Gains Losses | - | $-923,000 | - |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Capital Expenditure | $-109,000 | - | - |
| Investing Cash Flow | $-11,998,000 | $0 | $-1,000,000 |
| Cash Flow From Continuing Investing Activities | $-11,998,000 | $0 | $-1,000,000 |
| Net Other Investing Changes | - | - | $-1,000,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $85,000,000 | $0 | $225,000 |
| Financing Cash Flow | $81,991,000 | $0 | $225,000 |
| Cash Flow From Continuing Financing Activities | $81,991,000 | $0 | $225,000 |
| Net Other Financing Charges | $-3,341,000 | - | - |
| Net Preferred Stock Issuance | $85,000,000 | $0 | - |
| Preferred Stock Issuance | $85,000,000 | $0 | - |
| Net Common Stock Issuance | $332,000 | $0 | $225,000 |
| Common Stock Issuance | $332,000 | $0 | $225,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| End Cash Position | $61,641,000 | $9,735,000 | $15,559,000 |
| Beginning Cash Position | $9,735,000 | $15,559,000 | $26,877,000 |
| Changes In Cash | $51,906,000 | $-5,824,000 | $-11,318,000 |
| Proceeds From Stock Option Exercised | $332,000 | $0 | $225,000 |
| Net Investment Purchase And Sale | $-11,889,000 | $0 | - |
| Purchase Of Investment | $-11,889,000 | $0 | - |
| Net PPE Purchase And Sale | $-109,000 | $0 | - |
| Purchase Of PPE | $-109,000 | $0 | - |
| Change In Working Capital | $1,573,000 | $-81,000 | $-1,311,000 |
| Change In Other Current Liabilities | $-198,000 | $-100,000 | $-101,000 |
| Change In Payables And Accrued Expense | $2,183,000 | $774,000 | $-804,000 |
| Change In Accrued Expense | $1,385,000 | $-2,000 | $-835,000 |
| Change In Payable | $798,000 | $776,000 | $31,000 |
| Change In Account Payable | $798,000 | $776,000 | $31,000 |
| Change In Prepaid Assets | $-412,000 | $-755,000 | $-406,000 |
| Other Non Cash Items | $235,000 | $97,000 | $1,000,000 |
| Stock Based Compensation | $439,000 | $313,000 | $412,000 |
| Unrealized Gain Loss On Investment Securities | $217,000 | $1,216,000 | $2,321,000 |
| Provisionand Write Offof Assets | $117,000 | $762,000 | $489,000 |
| Amortization Of Securities | $-96,000 | $0 | - |
| Depreciation Amortization Depletion | $16,000 | $0 | $110,000 |
| Depreciation And Amortization | $16,000 | $0 | $110,000 |
| Depreciation | $16,000 | $0 | $110,000 |
| Net Income From Continuing Operations | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Gain Loss On Investment Securities | - | $-923,000 | - |